SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

September 17, 2022

Primary Completion Date

August 31, 2029

Study Completion Date

August 31, 2029

Conditions
Hepatitis D, Chronic
Interventions
DRUG

VIR-2218

VIR-2218 given by subcutaneous injection

DRUG

VIR-3434

VIR-3434 given by subcutaneous injection

DRUG

NRTI

NRTI given orally.

Trial Locations (20)

1010

Investigative Site, Auckland

1407

Investigative Site, Sofia

1431

Investigative Site, Sofia

6003

Investigative Site, Stara Zagora

20122

Investigative Site, Milan

30625

Investigative Site, Hanover

31000

Investigative Site, Toulouse

33600

Investigative Site, Pessac

35000

Investigative Site, Rennes

56124

Investigative Site, Pisa

60596

Investigative Site, Frankfurt

72076

Investigative Site, Tübingen

92110

Investigative Site, Clichy

MD-2025

Investigative Site, Chisinau

3015 GD

Investigative Site, Rotterdam

021105

Investigative Site, Bucharest

B15 2TT

Investigative Site, Birmingham

E1 1RF

Investigative Site, London

SE5 9RS

Investigative Site, London

M8 5RB

Investigative Site, Manchester

All Listed Sponsors
lead

Vir Biotechnology, Inc.

INDUSTRY